Nature Publishes Pre-Clinical Data on an Inhibitor of a Novel Target Discovered by Millennium
News Apr 09, 2009
The Takeda Oncology Company has announced publication of an article describing the discovery of MLN4924a small molecule inhibitor of the NEDD8-Activating Enzyme (NAE) in the journal Nature.
NAE modulates the level of proteins critical for the regulation of cancer cell growth and survival pathways. Preclinical data show that MLN4924 inhibition of NAE function alters these important cancer pathways and results in cancer cell death.
Data published in Nature demonstrate that MLN4924 not only inhibits detectable NAE pathway function in cancer cells in vitro but also does the same in human tumor xenografts in murine models leading to tumor growth inhibition at doses and schedules that were well tolerated. MLN4924 represents the first small molecule inhibitor to specifically target this class of enzyme.
“The work described in the Nature article highlights Millennium’s leadership in protein homeostasis research and drug discovery. It is very gratifying to see this science support the transition of MLN4924 into clinical development,” said Joseph B. Bolen, Ph.D., Chief Scientific Officer, Millennium. “This work is characteristic of our approach to defining new cancer drug targets and translating this information into new types of potential cancer therapeutics.”
“These preclinical results demonstrate that MLN4924 has potential in treating various types of cancer by selectively inducing apoptosis in cancer cells in in vivo animal models and in vitro cell assays,” said Teresa A. Soucy, Ph.D., lead author of the paper and senior scientist at Millennium. “The safety profile of MLN4924 now is being studied in Phase I trials in patients with solid tumors or hematologic malignancies.”
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018